Posts
July 24 2017
ImmunoCellular Therapeutics, Ltd. announced the closing of its public offering in the amount of $5,000,000. EG&S acted as counsel to Maxim Group LLC, the sole book-running manager for the offering.
July 21 2017
Trovagene, Inc., a precision medicine biotechnology company, announced the closing of their Registered Direct offering in the amount of $7.1 million. EG&S acted as counsel to Maxim Group LLC, the Sole Placement Agent for Trovagene.
July 21 2017
Cyclacel Pharmaceuticals Inc. announced the closing of their Underwritten offering in the amount of $4,306,360. EG&S acted as counsel to the Underwriter.
July 20 2017
The Deal issued its quarterly PIPE League Tables, revealing that the second quarter of 2017 saw 339 deals, raising $19.14 billion. The quarter was down from the comparable period last year, when the same number of deals yielded almost $24 billion after a rebound in oil prices sent energy companies roaring back into the market. Data is sourced from PrivateRaise, a service of The Deal, which tracks PIPEs that raise at least $1 million.
EG&S is top ranked. Click here to read the full article.
July 18 2017
Douglas S. Ellenoff, a member of the Firm, was interviewed by Crowdfund Insider on ICOs (Initial Coin Offerings). Read the full article here.
July 14 2017
EG&S was honored with ringing the Opening Bell at NASDAQ in celebration of our 25th Anniversary!
July 10 2017
Nxt-ID, Inc. announced the pricing of concurrent registered direct and private placement offerings yielding gross proceeds to the company of $3,432,000. EG&S acted as counsel to Aegis Capital Corp., the sole placement agent for these offerings.
July 07 2017
Yield10 Bioscience, Inc. announced the closing of their Registered Direct offering in the amount of $2,283,136. EG&S acted as counsel to the Placement Agent.